-
Checkmate: Starboard Boots Depomed CEO, Two Board Members
Wednesday, March 29, 2017 - 11:33am | 333Read More...Depomed Inc (NASDAQ: DEPO) and activist investor Starboard Value reached an agreement which will see the drugmaker name a new CEO and add two new members to its board. Despite the latest developments, analysts at Cantor Fitzgerald aren't ready to name the stock as a buy just yet. In a report...
-
Activist Investor Reaffirms Stance On Depomed, Says 'Meaningful Change Is Needed'
Friday, April 15, 2016 - 2:03pm | 255Read More...Starboard Value, an activist investment firm and major Depomed Inc (NASDAQ: DEPO) shareholder issued a statement Friday morning in response to the company's announcement that it has withdrawn its proposed reincorporation of the company from California to Delaware. The company said on...
-
Depomed Responds To Activist Investor, Notes Starboard Has Made No Contact With Management
Friday, April 8, 2016 - 2:32pm | 173Read More...Shares of Depomed Inc (NASDAQ: DEPO) were trading higher by more than 13 percent Friday afternoon after notable activist investment Starboard Value disclosed a large stake in the company. Related Link: Depomed Spikes 17% As Activist Investor Discloses Large Stake Depomed issued a brief response...
-
Dow Flirts With 19,000, S&P 500 Approaches 2,000 & NASDAQ Trading At 14-Year Highs
Tuesday, August 19, 2014 - 4:35pm | 2619Read More...U.S. stocks rose as geopolitical events took a back seat and investors found positives in housing and consumer price index data released Tuesday. The markets followed the lead of Apple which closed at an all-time split-adjusted high of $100.53. Earnings from Home Depot and TJX Companies also...
-
Depomed (DEPO) Shares Plummet Amid FDA Concerns
Thursday, February 18, 2010 - 8:07pm | 112Read More...Shares of pharmaceutical company Depomed, Inc. (Nasdaq: DEPO) fell today, amid FDA concerns and an analyst downgrade. The bad news began when fellow drugmaker XenoPort, Inc. (Nasdaq: XNPT) received a letter from the FDA stating that the company would not approve its gabapentin encarbil drug called...
